NCT05245084

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg

An Open Label, Randomized, Single Dose, 2-sequence, 4-period, Cross-over Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-386(3) With Co-administration of D013, D326, and D337 in Healthy Adult Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 64 (actual)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-386(3)

Detailed description

An open label, randomized, single dose, 2-sequence, 4-period, cross-over clinical trial to evaluate the pharmacokinetics and tolerability of CKD-386(3) with co-administration of D013, D326, and D337 in healthy adult volunteers

Conditions

• Hypertension and Dyslipidemia

Interventions

Type	Name	Description
DRUG	CKD-386(3)	QD, PO
DRUG	D013, D326, D337	QD, PO

Timeline

• Start date: 2022-03-15
• Primary completion: 2022-06-06
• Completion: 2022-06-20
• First posted: 2022-02-17
• Last updated: 2022-09-28

Locations

1 site across 1 country: South Korea